Alamar Biosciences, a company that is building the power of high-precision proteomics for early disease detection, is proud to announce the launch of the NULISAqpcr™ Custom Assay Development Kit, a groundbreaking product that will enable researchers to create highly sensitive and accurate biomarker assays tailored to their specific research needs and will expand application of NULISA™ technology to the wider biomarker research community.

The NULISAqpcr Custom Assay Development Kit provides unmatched flexibility, allowing scientists to use their own antibodies to develop targeted assays with exceptional sensitivity and reproducibility. This customizable kit is ideal for applications requiring high sensitivity and wide dynamic range, such as immunology, neurology, and others, providing a consistent workflow from antibody conjugation to automated sample processing via NULISAqpcr technology with the ARGO™ HT instrument, setting a new standard for self-development of single-component assays for in-house applications.

"The Custom Assay Development Kit is a direct response to the growing demand from researchers looking to leverage our cutting-edge NULISA technology in the development of high-performance biomarker assays for translational and clinical research," said Yuling Luo, Ph.D., founder, chairman, and CEO of Alamar Biosciences. "This launch marks an important milestone in our mission to create a transformative ecosystem for precision proteomics."

With the launch of NULISAqpcr Custom Assay Development Kits, Alamar continues to demonstrate its commitment to innovation and supporting the scientific community by providing cutting-edge solutions. Orders for the NULISAqpcr Custom Assay Development Kit are now being accepted with a delivery date of the second quarter.